Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.56 |
| ▸ | FLT3 | P36888 | 7/20 | 0.56 |
| ▸ | CSF1R | P07333 | 3/20 | 0.56 |
| ▸ | FLT4 | P35916 | 3/20 | 0.56 |
| ▸ | PLK4 | O00444 | 2/20 | 0.56 |
| ▸ | AURKA | O14965 | 2/20 | 0.56 |
| ▸ | JAK2 | O60674 | 2/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.56 |
| ▸ | CDK1 | P06493 | 2/20 | 0.56 |
| ▸ | MET | P08581 | 2/20 | 0.56 |
| ▸ | PRKACA | P17612 | 2/20 | 0.56 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.56 |
| ▸ | CDK2 | P24941 | 2/20 | 0.56 |
| ▸ | MARK3 | P27448 | 2/20 | 0.56 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.56 |
| ▸ | GSK3A | P49840 | 2/20 | 0.56 |
| ▸ | GSK3B | P49841 | 2/20 | 0.56 |
| ▸ | JAK3 | P52333 | 2/20 | 0.56 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2241313 | 0.89 | KDR (0.61) | KDRFLT3CSF1RFLT4PLK4 | |
| SCHEMBL2239738 | 0.88 | KDR (0.53) | KDRFLT3CSF1RFLT4AURKB | |
| SCHEMBL2239715 | 0.87 | KDR (0.51) | KDRFLT3CSF1RFLT4KIT | |
| SCHEMBL2237544 | 0.86 | KDR (0.60) | KDRFLT3CSF1RFLT4KIT | |
| SCHEMBL2235676 | 0.83 | KDR (0.60) | KDRFLT3CSF1RFLT4PLK4 | |
| SCHEMBL2818366 | 0.79 | KDR (0.69) | KDRFLT3CSF1RFLT4PLK4 | |
| SCHEMBL1702941 | 0.79 | KDR (0.75) | KDRFLT3CSF1RFLT4PLK4 | |
| SCHEMBL1703315 | 0.78 | KDR (0.70) | KDRFLT3CSF1RFLT4PLK4 | |
| SCHEMBL1703272 | 0.78 | KDR (0.72) | KDRFLT3CSF1RFLT4PLK4 | |
| SCHEMBL2236724 | 0.78 | KDR (0.58) | KDRFLT3CSF1RFLT4CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190337-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A.. (FR) | 2011-08-04 | — | — | US | claimed |
| EP-1845978-B1 | SUBSTITUTED PYRAZOLO-PYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA SA (FR) | 2010-08-18 | — | — | EP | claimed |
| US-20080039491-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2008-02-14 | — | — | US | claimed |
| US-8008322-B2 | Substituted pyrazolopyridines, compositions containing them, method for the production thereof, and their use | AVENTIS PHARMA S.A. (FR) | 2011-08-30 | — | — | US | disclosed |
| US-8008322-B2 | Substituted pyrazolopyridines, compositions containing them, method for the production thereof, and their use | AVENTIS PHARMA S.A. (FR) | 2011-08-30 | — | — | US | disclosed |
| US-8008322-B2 | Substituted pyrazolopyridines, compositions containing them, method for the production thereof, and their use | AVENTIS PHARMA S.A. (FR) | 2011-08-30 | — | — | US | disclosed |
| US-20110190337-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A.. (FR) | 2011-08-04 | — | — | US | disclosed |
| US-20110190337-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A.. (FR) | 2011-08-04 | — | — | US | disclosed |
| US-20110190337-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A.. (FR) | 2011-08-04 | — | — | US | disclosed |
| EP-1845978-B1 | SUBSTITUTED PYRAZOLO-PYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA SA (FR) | 2010-08-18 | — | — | EP | disclosed |
| US-20080039491-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2008-02-14 | — | — | US | disclosed |
| US-20080039491-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2008-02-14 | — | — | US | disclosed |
| US-20080039491-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190337-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | DPYD, TYMP, PCK2 | KDR 2947/4885FLT3 121/4885CSF1R 4531/4885 |
| US-20080039491-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | DPYD, TYMP, PCK2 | KDR 2947/4885FLT3 121/4885CSF1R 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.